Co-expression network analysis of the lncRNAs and mRNAs associated with cervical cancer progression

Li Jiang, Li Hong, Wenwu Yang, Yuzi Zhao, Aili Tan, Yang Li

Department of Gynaecology and Obstetrics, Renmin Hospital of Wuhan University, Wuhan, China

Submitted: 22 June 2018
Accepted: 7 August 2018

Arch Med Sci 2019; 15 (3): 754–764
DOI: https://doi.org/10.5114/aoms.2019.84740
Copyright © 2019 Termedia & Banach

Abstract

Introduction: Cervical cancer is the second most common type of cancer and the third leading cause of cancer deaths in females in developing countries. Recent studies showed that long non-coding RNAs play a key role in human cancers. However, the molecular mechanisms underlying the initiation and progression of cervical cancer remained to be further explored.

Material and methods: In this study, we explored the differential expression of lncRNAs and mRNAs in cervical cancer progression by analyzing the public dataset GSE63514. Next, PPI and co-expression networks were constructed to reveal the potential roles of cervical cancer related mRNAs and lncRNAs. Furthermore, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was performed to explore functions of differentially expressed genes (DEGs) in cervical cancer.

Results: In the present study, we observed that 3021 mRNAs were up-regulated and 1605 mRNAs were down-regulated in cervical cancer progression. Meanwhile, we for the first time found that 172 lncRNAs were up-regulated and 106 lncRNAs were down-regulated in cervical cancer progression. Co-expression network analysis showed that lncRNAs were widely co-expressed with cell cycle related genes in cervical cancer, implicating the important roles of these lncRNAs in cell proliferation regulation. Of note, we identified two hub lncRNA-mRNA networks involved in regulating various biological processes in cervical cancer progression.

Conclusions: Our results identified key mRNAs and lncRNAs in cervical cancer progression. This study will provide novel insights to explore the potential mechanisms underlying cervical cancer progression.

Key words: long non-coding RNAs, cervical cancer, protein-protein interaction analysis, expression profiling.

Introduction

Cervical cancer is the second most common type of cancer and the third leading cause of cancer deaths in women in developing countries [1–3]. Previous studies had revealed that transcription factors, miRNAs, and RNA binding proteins were involved in cervical cancer progression. For example, AP-2β suppressed cervical cancer cell proliferation by inducing the degradation of β-catenin [4], and microRNA-221-3p promoted cervical cancer metastasis by targeting THBS2 [5]. However, the molecular mechanisms underlying the initiation and progression of cervical cancer remained to be further explored.
Long non-coding RNAs (lncRNAs) were a type of non-coding RNAs more than 200 nucleotides in length [6, 7]. Interestingly, several studies showed that a few lncRNAs had protein coding potential. Recent reports demonstrated the important roles of lncRNAs in cancer progression [8]. LncRNAs were differently expressed in various human cancers, such as prostate cancer, lung cancer and breast cancer, and were involved in regulating widespread biological processes, including cell proliferation, apoptosis, metastasis and autophagy [9–11]. In cervical cancer, lncRNAs had been revealed to be involved in tumor proliferation, radio-resistance and metastasis regulation. For example, HOTAIR promoted HeLa cell migration and invasion by inhibiting miR206 [12], and HOXD-AS1 regulated cervical cancer proliferation by activating Ras/ERK signaling [13]. However, the roles of lncRNAs in cervical cancer progression remained to be further explored.

In the present study, we aimed to identify differentially expressed lncRNAs and mRNAs in cervical cancer progression by analyzing the public dataset GSE63514, including 24 normal, 14 CIN1 lesions, 22 CIN2 lesions, 40 CIN3 lesions, and 28 cervical cancer samples. We constructed a protein-protein interaction network and lncRNA co-expression network to reveal the potential roles of cervical cancer related mRNAs and lncRNAs. This study will provide useful information to explore the potential candidate biomarkers for diagnosis, prognosis, and drug targets for cervical cancer.

Material and methods

Microarray data and data preprocessing

In this study, we downloaded a public dataset, GSE63514 [14], from NCBI GEO datasets (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE63514). GSE63514 dataset including 24 normal, 14 CIN1 lesions, 22 CIN2 lesions, 40 CIN3 lesions, and 28 cervical cancer samples. All samples were cryosectioned and used for laser-capture, RNA extraction, two rounds of T7-mediated amplification, and cRNA biotinylation. Then, cRNA was hybridized to Affymetrix U133-Plus 2.0 arrays, and scanned signals were processed through GC-RMA. We used the limma package in R software to normalize the raw data (https://www.r-project.org/). The differentially expressed mRNA and LncRNA were identified by the linear models for microarray analysis (limma) method [15]. The gene expression among 24 normal, 14 CIN1 lesions, 22 CIN2 lesions, 40 CIN3 lesions, and 28 cervical cancer samples with thresholds of $|\log FC| > 1.5$ and $p < 0.001$ were identified to be differentially expressed. Hierarchical cluster analysis of differentially expressed mRNAs and lncRNAs was performed using CLUSTER 3.0, and the hierarchical clustering heat map was visualized by Tree View [16].

LncRNA classification pipeline

Previous studies indicated many mRNA microarray datasets including many long non-coding RNAs probes. In this study, we screened differently expressed lncRNAs in cervical cancer progression by applying a pipeline reported by Zhang et al. [17]. Briefly, first, the GPL570 platform of Affymetrix Human Genome U133 Plus 2.0 Array (Affymetrix Inc., Santa Clara, California, USA) probe set ID was mapped to the NetAffx Annotation Files (HG-U133 Plus 2.0 Annotations, CSV format, release 31, 08/23/10). The annotations included the probe set ID, gene symbol, and Refseq transcript ID. Second, the probe sets that were assigned with a Refseq transcript ID in the NetAffx annotations were extracted. In this study, we only retained those labeled as “NR_” (NR indicates non-coding RNA in the Refseq database). Finally, 2448 annotated lncRNA transcripts with corresponding Affymetrix probe IDs were generated. LncRNAs having fold changes ≥ 2 and $p < 0.05$ were selected as of significantly differential expression.

GO and KEGG pathway analysis

To identify functions of DEGs in cervical cancer, we performed GO function enrichment analysis in 3 functional ontologies: biological process (BP), cellular component (CC) and molecular function (MF). KEGG pathway enrichment analysis was also performed to identify pathways enriched in smoking related lung cancer using the DAVID system (https://david.ncifcrf.gov/). The p-value less than 0.05 was considered as significant.

Construction of PPI network and module analysis

In order to predict protein interactions, which included physical and functional associations, the present study used the Search Tool for the Retrieval of Interacting Genes (STRING) to construct the PPI network for DEGs (minimum required interaction score > 0.4) [18]. The interaction relationships of the proteins encoded by DEGs were searched by STRING online software, and the combined score > 0.4 was used as the cut-off criterion. In addition, Cytoscape software version 3.4.0 (http://cytoscape.org/download_old_versions.html) was used for visualization of the PPI networks [19]. Following the construction of the PPI network, a module analysis of the network was performed using the MCODE plug-in (degree cut-off ≥ 2 and the nodes with edges ≥ 2-core) [20]. Additionally, the Network Analyzer was used...
to compute the basic properties of the PPI network, including average clustering co-efficient distribution, closeness centrality, average neighborhood connectivity, node degree distribution, shortest path length distribution, and topological coefficients [21].

Co-expression network construction and analysis

In this study, the Pearson correlation coefficient of DEG-IncRNA pairs was calculated according to their expression value. The co-expressed DEG-IncRNA pairs with the absolute value of Pearson correlation coefficient ≥ 0.75 were selected and the co-expression network was established using Cytoscape software. Cytoscape MCODE plug-in (Version 3.4.0, available online: http://www.cytoscape.org/) was applied for visualization of the co-expression networks.

Statistical analysis

All statistical analysis of this research was carried out using SPSS 18.0 statistical software. Statistical comparisons between groups of normalized data were performed using the t-test or Mann-Whitney U-test according to the test condition. A p < 0.05 was considered statistically significant with a 95% confidence level.

Results

Identification of differentially expressed mRNAs and IncRNAs in cervical cancer

In the present study, we analyzed the GSE63514 dataset to identify differentially expressed genes in cervical cancer progression. The gene expression with |logFC| > 1 and p < 0.05 among 24 normal samples, 14 CIN1 lesions, 22 CIN2 lesions, 40 CIN3 lesions, and 28 cervical cancer samples was identified to be differentially expressed. A total of 4799 mRNAs were identified as cervical cancer progression related genes. Among these mRNAs, 3021 mRNAs were up-regulated and 1605 mRNAs were down-regulated in cervical cancer progression. The top up-regulated and down-regulated 10 mRNAs involved in cervical cancer progression are listed in Tables I and II. As shown in Figure 1 A, hierarchical clustering analysis was performed to show the DEGs in the progression of cervical cancer from normal to cancer.

Here, we found that GSE63514 provided a good platform to evaluate the functional roles of IncRNAs in cervical cancer tumorigenesis. After applying the IncRNA classification pipeline reported by Zhang et al., 3687 IncRNA probes were found in the GSE63514 dataset. We then compared the IncRNA expression patterns between normal and all grades of lesions. We for the first time found that 278 IncRNAs were associated with cervical cancer progression. Among these IncRNAs, 172 IncRNAs were up-regulated and 106 IncRNAs were down-regulated in the cervical cancer progression. Of note, several IncRNAs, including TUG1, MEG3 and XIST, had been reported to be associated with cervical cancer proliferation and metastasis. The top up-regulated and down-regulated 10 IncRNAs involved in cervical cancer progression are listed in Tables III and IV. Hierarchical clustering analysis of the IncRNAs in cervical cancer is shown in Figure 1 B.

Construction of PPI networks for differentially expressed mRNAs in cervical cancer

We constructed the protein-protein interaction network analysis for 4799 differently expressed mRNAs by using the STRING database. We then used the Mcode plug-in to identify key networks with degree cut-off ≥ 2 and the nodes with edges ≥ 2-core in the total PPI network. The top 5 up-regulated hub-networks and top 3 down-regulated hub-networks are shown in Figure 2.

Co-expression network analysis of differently expressed IncRNAs in cervical cancer progression

We next constructed the gene co-expression network between IncRNAs and mRNAs in cervical cancer progression. We performed the correlation analysis for mRNAs and IncRNAs by calculating the Pearson correlation coefficient in all samples and selected IncRNA-mRNA pairs with |R| > 0.65 for co-expression network construction. As shown in Figure 3, a total of 278 IncRNAs and 786 mRNAs were included in this network. Interestingly, we observed many antisense IncRNAs co-expressed with sense mRNAs, including the MFI2-AS1-MFI2 pair, PSMB8-AS1-PSMB9 pair, and HOXB-AS3-HOXB6 pair (Figure 3 A). Several well-known IncRNAs, such as MALAT1 and DLEU2, were also revealed to play important roles in cervical cancer progression (Figure 3 B). Among these IncRNAs, IncRNA RP11-173B14.4, RP11-308D16.4, LOC100630918, and RP13-270P17.3 were identified as key IncRNAs in this network by regulating about 190 mRNAs (Figure 3 C).

GO and KEGG analysis of differentially expressed IncRNAs in cervical cancer progression

Furthermore, we performed GO and KEGG analysis for differentially expressed IncRNAs (Figures 4 A–C). GO analysis showed that differentially expressed IncRNAs were mainly involved in
Table I. The top 10 up-regulated mRNAs in cervical cancer progression

| Gene name | Ave (normal) | Ave (CIN1) | Ave (CIN2) | Ave (CIN3) | Ave (tumor) | FC (CIN1 vs. normal) | FC (CIN2 vs. normal) | FC (CIN3 vs. normal) | FC (tumor vs. normal) | P (CIN1 vs. normal) | P (CIN2 vs. normal) | P (CIN3 vs. normal) | P (tumor vs. normal) |
|-----------|--------------|------------|------------|------------|-------------|---------------------|---------------------|---------------------|---------------------|------------------|-------------------|-------------------|-------------------|
| NUP210    | 2.97         | 4.34       | 5.59       | 7.33       | 7.44         | 2.58                | 3.06                | 22.58               | 22.22               | < 0.001          | < 0.001           | < 0.001           | < 0.001           |
| MMP12     | 3.83         | 5.28       | 5.70       | 7.25       | 7.68         | 2.73                | 3.65                | 16.05               | 16.10               | 0.10             | 0.02              | < 0.001           | < 0.001           |
| SYNGR3    | 3.50         | 5.39       | 6.12       | 8.20       | 8.35         | 2.72                | 3.86                | 16.56               | 16.92               | 0.10             | < 0.001           | < 0.001           | < 0.001           |
| HS6ST2    | 4.40         | 6.53       | 8.23       | 8.58       | 9.53         | 2.74                | 4.55                | 25.92               | 27.36               | 0.01             | < 0.001           | < 0.001           | < 0.001           |
| ZIC2      | 2.79         | 3.22       | 4.96       | 8.58       | 9.62         | 2.49                | 3.56                | 24.22               | 25.52               | 0.02             | < 0.001           | < 0.001           | < 0.001           |
| CTNNB1    | 5.95         | 6.34       | 7.68       | 10.48      | 10.31        | 2.65                | 3.95                | 14.66               | 15.31               | 0.05             | < 0.001           | < 0.001           | < 0.001           |
| ELB1       | 2.31        | 3.22       | 4.26       | 7.49       | 8.06         | 2.73                | 3.71                | 12.53               | 13.32               | 0.06             | < 0.001           | < 0.001           | < 0.001           |
| SYCP2     | 4.11        | 5.36       | 7.57       | 9.23       | 9.72         | 2.72                | 3.73                | 14.53               | 15.24               | 0.01             | < 0.001           | < 0.001           | < 0.001           |
| CDKN2A    | 4.07        | 6.90       | 10.03      | 10.67      | 10.47        | 2.71                | 3.94                | 39.46               | 40.34               | 0.02             | < 0.001           | < 0.001           | < 0.001           |

Table II. The top 10 down-regulated mRNAs in cervical cancer progression

| Gene name | Ave (normal) | Ave (CIN1) | Ave (CIN2) | Ave (CIN3) | Ave (tumor) | FC (CIN1 vs. normal) | FC (CIN2 vs. normal) | FC (CIN3 vs. normal) | FC (tumor vs. normal) | P (CIN1 vs. normal) | P (CIN2 vs. normal) | P (CIN3 vs. normal) | P (tumor vs. normal) |
|-----------|--------------|------------|------------|------------|-------------|---------------------|---------------------|---------------------|---------------------|------------------|-------------------|-------------------|-------------------|
| CRISP3    | 12.23        | 9.88       | 10.49      | 7.67       | 4.31         | 1.76                | 3.59                | 3.16                | 0.38                | < 0.001           | < 0.001           | < 0.001           | < 0.001           |
| CRISP2    | 8.02         | 4.72       | 5.37       | 3.64       | 1.21         | 0.59                | 0.95                | 0.91                | 0.11                | < 0.001           | < 0.001           | < 0.001           | < 0.001           |
| RPTN      | 8.05         | 4.72       | 5.37       | 3.64       | 1.21         | 0.59                | 0.95                | 0.91                | 0.11                | < 0.001           | < 0.001           | < 0.001           | < 0.001           |
| UPK1A     | 8.11         | 6.41       | 5.96       | 4.35       | 3.95         | 1.23                | 1.00                | 0.88                | 0.84                | < 0.001           | < 0.001           | < 0.001           | < 0.001           |
| ZBED2     | 8.14         | 6.60       | 5.60       | 4.44       | 3.53         | 1.20                | 1.00                | 0.88                | 0.84                | < 0.001           | < 0.001           | < 0.001           | < 0.001           |
| LCE3D     | 10.36        | 8.04       | 8.73       | 7.30       | 6.00         | 1.25                | 1.00                | 0.88                | 0.84                | < 0.001           | < 0.001           | < 0.001           | < 0.001           |
| CRCT1     | 8.67         | 7.13       | 6.64       | 5.25       | 3.93         | 1.30                | 1.00                | 0.88                | 0.84                | < 0.001           | < 0.001           | < 0.001           | < 0.001           |
| KRT2      | 8.22         | 6.83       | 5.58       | 5.20       | 5.79         | 1.34                | 1.00                | 0.88                | 0.84                | < 0.001           | < 0.001           | < 0.001           | < 0.001           |
| EPB41L3   | 8.22         | 6.83       | 5.58       | 5.20       | 5.79         | 1.34                | 1.00                | 0.88                | 0.84                | < 0.001           | < 0.001           | < 0.001           | < 0.001           |
| OAS2      | 6.09         | 4.65       | 4.29       | 3.17       | 2.35         | 0.71                | 0.71                | 0.88                | 0.84                | < 0.001           | < 0.001           | < 0.001           | < 0.001           |
regulating transcription, cell division, DNA repair, mRNA splicing, via spliceosome, cellular response to DNA damage stimulus, DNA replication, G2/M transition of mitotic cell cycle, regulation of the cell cycle, sister chromatid cohesion, and double-strand break repair.

KEGG pathway analysis revealed that cervical cancer progression related lncRNAs were primarily enriched in pathways associated with the cell cycle, focal adhesion, RNA transport, Wnt signaling pathway, DNA repair, G2/M transition of mitotic cell cycle, regulation of the cell cycle, sister chromatid cohesion, and double-strand break repair.

KEGG pathway analysis revealed that cervical cancer progression related lncRNAs were primarily enriched in pathways associated with the cell cycle, focal adhesion, RNA transport, Wnt signaling pathway, DNA repair, G2/M transition of mitotic cell cycle, regulation of the cell cycle, sister chromatid cohesion, and double-strand break repair.

**Discussion**

Cervical cancer is one of the most common types of cancer in females [1]. However, the molecular mechanisms underlying the initiation and progression of cervical cancer remained to be further explored. In this study, we analyzed the GSE63514 dataset to identify differentially expressed genes in cervical cancer progression. We observed that 3021 mRNAs were up-regulated and 1605 mRNAs were down-regulated in cervical cancer progression. Meanwhile, we for the first time found that 172 lncRNAs were up-regulated and 106 lncRNAs were down-regulated in cervical cancer progression.
### Table III. The top 10 up-regulated lncRNAs in cervical cancer progression

| Gene name     | Ave (normal) | Ave (CIN1) | Ave (CIN2) | Ave (CIN3) | Ave (tumor) | FC (CIN1 vs. normal) | FC (CIN2 vs. normal) | FC (CIN3 vs. normal) | FC (tumor vs. normal) | P (CIN1 vs. normal) | P (CIN2 vs. normal) | P (CIN3 vs. normal) | P (tumor vs. normal) |
|---------------|--------------|------------|------------|------------|-------------|----------------------|----------------------|----------------------|----------------------|---------------------|---------------------|---------------------|----------------------|
| RP11-1L12.3   | 2.78         | 3.90       | 4.28       | 5.58       | 5.23        | 2.16                 | 2.82                 | 6.96                 | 5.46                 | 0.07                | 0.02                | < 0.001             | < 0.001             |
| LINC01305     | 2.59         | 3.24       | 4.01       | 5.41       | 5.46        | 1.57                 | 2.67                 | 7.06                 | 7.31                 | 0.09                | 0.03                | < 0.001             | < 0.001             |
| LOC375196     | 2.87         | 3.44       | 4.47       | 6.16       | 5.69        | 1.49                 | 3.04                 | 9.83                 | 7.08                 | 0.19                | < 0.001             | < 0.001             | < 0.001             |
| ANKRD36BP2    | 5.03         | 7.32       | 6.26       | 7.00       | 8.65        | 4.90                 | 2.35                 | 3.93                 | 12.34                | 0.01                | 0.07                | 0.01                | < 0.001             |
| LINC00925     | 3.07         | 3.72       | 4.91       | 7.00       | 5.82        | 1.57                 | 3.57                 | 15.19                | 6.71                 | 0.16                | < 0.001             | < 0.001             | < 0.001             |
| CTA-384D8.35  | 2.59         | 4.04       | 3.93       | 6.29       | 6.50        | 2.73                 | 2.52                 | 12.96                | 14.96                | < 0.001             | < 0.001             | < 0.001             | < 0.001             |
| ABCA17P       | 2.92         | 4.58       | 5.28       | 7.56       | 6.72        | 3.17                 | 5.15                 | 24.98                | 13.97                | 0.01                | < 0.001             | < 0.001             | < 0.001             |
| TCAM1P        | 3.30         | 4.71       | 6.62       | 8.09       | 7.94        | 2.66                 | 9.97                 | 27.68                | 24.85                | 0.01                | < 0.001             | < 0.001             | < 0.001             |
| RPI-93H18.6   | 4.64         | 5.97       | 5.64       | 6.94       | 6.97        | 2.51                 | 2.01                 | 4.94                 | 5.04                 | 0.01                | 0.02                | < 0.001             | < 0.001             |
| AC128677.4    | 2.78         | 3.43       | 3.61       | 4.83       | 5.54        | 1.57                 | 1.77                 | 4.15                 | 6.77                 | 0.22                | 0.12                | < 0.001             | < 0.001             |

### Table IV. The top 10 down-regulated lncRNAs in cervical cancer progression

| Gene name     | Ave (normal) | Ave (CIN1) | Ave (CIN2) | Ave (CIN3) | Ave (tumor) | FC (CIN1 vs. normal) | FC (CIN2 vs. normal) | FC (CIN3 vs. normal) | FC (tumor vs. normal) | P (CIN1 vs. normal) | P (CIN2 vs. normal) | P (CIN3 vs. normal) | P (tumor vs. normal) |
|---------------|--------------|------------|------------|------------|-------------|----------------------|----------------------|----------------------|----------------------|---------------------|---------------------|---------------------|----------------------|
| CYP2B7P       | 7.43         | 6.38       | 5.77       | 5.19       | 4.23        | 0.48                 | 0.32                 | 0.21                 | 0.11                 | 0.30                | 0.06                | < 0.001             | < 0.001             |
| PRSS3P2       | 7.03         | 5.98       | 5.85       | 4.25       | 4.01        | 0.48                 | 0.44                 | 0.15                 | 0.12                 | 0.03                | < 0.001             | < 0.001             | < 0.001             |
| RAB11B-AS1    | 7.15         | 6.14       | 6.03       | 4.75       | 3.99        | 0.50                 | 0.46                 | 0.19                 | 0.11                 | 0.07                | 0.02                | < 0.001             | < 0.001             |
| LINC01214     | 4.51         | 3.38       | 3.15       | 2.65       | 2.44        | 0.46                 | 0.39                 | 0.28                 | 0.24                 | 0.16                | 0.02                | < 0.001             | < 0.001             |
| RP11-77403.3  | 5.60         | 4.84       | 4.43       | 3.16       | 3.06        | 0.59                 | 0.44                 | 0.18                 | 0.17                 | 0.17                | 0.02                | < 0.001             | < 0.001             |
| HCG22         | 5.20         | 3.73       | 4.31       | 3.40       | 3.15        | 0.36                 | 0.54                 | 0.29                 | 0.24                 | 0.05                | 0.17                | < 0.001             | < 0.001             |
| ZNF300P1      | 7.06         | 6.53       | 5.79       | 4.90       | 3.90        | 0.69                 | 0.41                 | 0.22                 | 0.11                 | 0.11                | 0.03                | < 0.001             | < 0.001             |
| FLG-AS1       | 7.34         | 6.64       | 6.48       | 4.81       | 4.00        | 0.62                 | 0.55                 | 0.17                 | 0.10                 | 0.33                | 0.20                | < 0.001             | < 0.001             |
| LOC100507487  | 6.58         | 6.24       | 5.39       | 3.62       | 3.50        | 0.79                 | 0.44                 | 0.13                 | 0.12                 | 0.62                | 0.02                | < 0.001             | < 0.001             |
| LINC01094     | 5.37         | 4.78       | 4.13       | 3.55       | 3.60        | 0.66                 | 0.42                 | 0.28                 | 0.29                 | 0.48                | 0.07                | < 0.001             | < 0.001             |
Previous studies had revealed that several proteins were involved in regulating cervical cancer progression. For example, GADD45α increased cytoplasmic APE1 levels to sensitize cervical cancer cells to radiotherapy [22]. PD-L1 was found to promote glucose metabolism in cervical cancer [23]. However, there was still no system-wide identification of cervical cancer progression related genes. Here, we analyzed the GSE63514 dataset, which included 24 normal samples, 14 CIN1 lesions, 22 CIN2 lesions, 40 CIN3 lesions, and 28 cervical cancer samples. A total of 3021 mRNAs were up-regulated and 1605 mRNAs were down-regulated in cervical cancer progression. In order to explore the potential roles of these genes, we constructed PPI networks. Our results showed that several genes, including CDK1, OIP5, NCAPG, CCNA2, AURKB and HMMR, played key roles in cervical cancer progression.

Recent studies showed lncRNAs played crucial roles in tumor proliferation, apoptosis, metastasis, and invasion. In cervical cancer, several lncRNAs were found to be dysregulated in tumor samples. For instance, IncRNA PCAT-1 regulated cervical cancer cell proliferation, metastasis, and invasion [24]. Silencing HOXD-AS1 remarkably suppressed proliferation of cervical cancer cells by regulating Ras/ERK signaling [13]. IncRNA TUG1 promoted...
Figure 3. Co-expression network analysis of differentially expressed lncRNAs in cervical cancer progression. The gene co-expression network between lncRNAs and mRNAs in cervical cancer progression. 278 lncRNAs and 786 mRNAs were included in this network.
cervical cancer progression by affecting the miR-138-5p-SIRT1 axis [25]. Meanwhile, HOTAIR was reported to be an oncogene to promote cervical cancer growth and migration [26]. However, the roles of lncRNAs in cervical cancer progression remained unclear. In this study, we identified 172 lncRNAs that were up-regulated and 106 lncRNAs that were down-regulated in cervical cancer progression. Of note, several lncRNAs, including TUG1, MEG3 and XIST, had been reported to be associated with cervical cancer proliferation and metastasis [27, 28]. However, most of these lncRNAs were never reported in human cancers. Our study for the first time comprehensively revealed cervical cancer progression related lncRNAs.

The function roles of most lncRNAs remained largely unclear. Recently, gene co-expression network analysis was widely used to evaluate potential roles of lncRNAs. For example, Du et al. [29] performed lncRNA-mRNA co-expression analysis in thyroid cancer and Li et al. [30] constructed lncRNAs and circRNAs mediated co-expression and ceRNA networks in mouse germline stem cells. Here, we also performed co-expression network analysis of differentially expressed lncRNAs in cervical cancer progression. Interestingly, we observed many antisense lncRNAs co-expressed with sense mRNAs, including the MFI2-AS1-MFI2 pair, PSMB8-AS1-PSMB9 pair, and HOXB-AS3-HOXB6 pair. Bioinformatics analysis showed that these lncRNAs played important roles in regulating the cell cycle, cell division, DNA repair, and mRNA splicing. Moreover, we identified two hub lncRNA-mRNA networks. Hub network 1 was involved in regulating the cell cycle, cellular response to DNA damage stimulus, chromosome organization, and the immune response, and Hub l network 2 was involved in regulating Th1 and Th2 cell differentiation and the Wnt signaling pathway.

In conclusion, we identified that 4799 mRNAs and 278 lncRNAs were differentially expressed in cervical cancer progression. Co-expression network analysis showed that lncRNAs were widely co-expressed with cell cycle related genes in cervical cancer, implicating the important roles of these lncRNAs in cell proliferation regulation. Of note, we identified two hub lncRNA-mRNA networks. We believe that our analysis could provide novel insights to explore the potential mechanisms underlying cervical cancer progression.

**Conflict of interest**

The authors declare no conflict of interest.
Figure 5. Functional prediction of key lncRNA-mRNAs network. A – Hub lncRNA-mRNAs network 1 was involved in regulating Th1 and Th2 cell differentiation, Wnt signaling pathway, glycosaminoglycan biosynthesis and protein O-linked glycosylation. B – Hub lncRNA-mRNAs network 2 was involved in regulating cell cycle, cellular response to DNA damage stimulus, chromosome organization, and immune response.
References

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.

2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: Cancer J Clin 2011; 61: 69-90.

3. Baoning Q, Chuandao S, Na S, Xinan W, Yuanping H. Efficacy and safety of radio-chemotherapy combined with thermotherapy for advanced cervical cancer in Chinese women: a meta-analysis. Arch Med Sci Civil Dis 2017; 2: 182-90.

4. Wang F, Huang W, Hu X, et al. Transcription factor AP-2beta suppresses cervical cancer cell proliferation by promoting the degradation of its interaction partner beta-catenin. Mol Carcinog 2017; 56: 1909-23.

5. Wei W, Zhou C, Wu XG, et al. MicroRNA-221-3p, a TWIST2 target, promotes cervical cancer metastasis by directly targeting THBS2. Cell Death Dis 2017; 8: 3220.

6. Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. Science 2005; 309: 1519-24.

7. Kornienko AE, Guenzl PM, Barlow DP, Pauler FM. Gene regulation by the act of long non-coding RNA transcription. BMC Biol 2013; 11: 11.

8. Wang F, Huang W, Hu X, et al. MicroRNA-221-3p, a TWIST2 target, promotes cervical cancer metastasis by directly targeting THBS2. Cell Death Dis 2017; 8: 3220.

9. Wang F, Hu X, et al. Transcription factor AP-2beta suppresses cervical cancer cell proliferation by promoting the degradation of its interaction partner beta-catenin. Mol Carcinog 2017; 56: 1909-23.

10. Wei W, Zhou C, Wu XG, et al. MicroRNA-221-3p, a TWIST2 target, promotes cervical cancer metastasis by directly targeting THBS2. Cell Death Dis 2017; 8: 3220.

11. Wang F, Huang W, Hu X, et al. Transcription factor AP-2beta suppresses cervical cancer cell proliferation by promoting the degradation of its interaction partner beta-catenin. Mol Carcinog 2017; 56: 1909-23.

12. Wei W, Zhou C, Wu XG, et al. MicroRNA-221-3p, a TWIST2 target, promotes cervical cancer metastasis by directly targeting THBS2. Cell Death Dis 2017; 8: 3220.

13. Wang F, Huang W, Hu X, et al. Transcription factor AP-2beta suppresses cervical cancer cell proliferation by promoting the degradation of its interaction partner beta-catenin. Mol Carcinog 2017; 56: 1909-23.

14. Wei W, Zhou C, Wu XG, et al. MicroRNA-221-3p, a TWIST2 target, promotes cervical cancer metastasis by directly targeting THBS2. Cell Death Dis 2017; 8: 3220.

15. Wang F, Huang W, Hu X, et al. Transcription factor AP-2beta suppresses cervical cancer cell proliferation by promoting the degradation of its interaction partner beta-catenin. Mol Carcinog 2017; 56: 1909-23.

16. Wei W, Zhou C, Wu XG, et al. MicroRNA-221-3p, a TWIST2 target, promotes cervical cancer metastasis by directly targeting THBS2. Cell Death Dis 2017; 8: 3220.

17. Wang F, Huang W, Hu X, et al. Transcription factor AP-2beta suppresses cervical cancer cell proliferation by promoting the degradation of its interaction partner beta-catenin. Mol Carcinog 2017; 56: 1909-23.

18. Wei W, Zhou C, Wu XG, et al. MicroRNA-221-3p, a TWIST2 target, promotes cervical cancer metastasis by directly targeting THBS2. Cell Death Dis 2017; 8: 3220.

19. Wang F, Huang W, Hu X, et al. Transcription factor AP-2beta suppresses cervical cancer cell proliferation by promoting the degradation of its interaction partner beta-catenin. Mol Carcinog 2017; 56: 1909-23.

20. Wei W, Zhou C, Wu XG, et al. MicroRNA-221-3p, a TWIST2 target, promotes cervical cancer metastasis by directly targeting THBS2. Cell Death Dis 2017; 8: 3220.

21. Wei W, Zhou C, Wu XG, et al. MicroRNA-221-3p, a TWIST2 target, promotes cervical cancer metastasis by directly targeting THBS2. Cell Death Dis 2017; 8: 3220.